TCR2 Therapeutics Inc. announced the appointment of Priti Hegde, Ph.D., to its board of directors. Dr. Hegde brings to the company over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde’s arrival, Patrick Baeuerle, Ph.D., will be stepping down from the board of directors effective August 24, 2021 but will continue to serve the company in an advisory capacity. Dr. Hegde currently serves as Chief Scientific Officer at Foundation Medicine Inc. Previously, Dr. Hegde held roles of increasing responsibility at Genentech for 12 years. Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline.